The effect and safety of ropinirole in the treatment of Parkinson disease

Abstract

Background:It is necessary to conduct a meta-analysis of the clinical randomized controlled trials (RCTs) on ropinirole in the treatment of Parkinson disease (PD), to explore the effects and safety of ropinirole, and to provide a theoretical basis for clinically safe and rational drug use.Methods:RCTs on the effectiveness and safety of ropinirole in the treatment of PD were searched. We searched Dutch medical literature database, Pubmed, Cochrane Library, China National Knowledge Infrastructure, Wanfang Knowledge Service Platform up to December 15, 2020. The Cochrane risk bias assessment tool was used to evaluate the quality of the included literature, and the RevMan5.3 software was used for meta-analysis.Results:A total of 12 RCTs with 3341 patients were included. The changes of Parkinson Disease Rating Scale Part II score (mean difference = –2.23, 95% confidence interval [CI] –2.82 to –1.64) and Parkinson Disease Rating Scale Part III scores (mean difference = –4.93, 95%CI –5.25 to –4.61) in the ropinirole group was significantly lower than that in the control group. The incidence of dizziness (odd risk [OR] = 1.85, 95%CI 1.50–2.28), nausea (OR = 2.17, 95%CI 1.81–2.59), vomiting (OR = 2.73, 95%CI 1.47–5.09), and lethargy (OR = 2.19, 95%CI 1.39–3.44) in the ropinirole group was significantly higher than that in the control group (all P < .05), and there were no significant differences in the incidence of headache (OR = 1.14, 95%CI 0.79–1.65) and insomnia (OR = 1.06, 95%CI 0.72–1.55) were found between 2 groups (all P > .05).Conclusions:Ropinirole can help improve the ability of daily living and exercise function of PD patients, but it will increase the incidence of related adverse reactions, which needs to be further confirmed by subsequent large-scale, high-quality RCTs.

Comparative efficacy and safety of six non-ergot dopamine-receptor agonists in early Parkinson's disease: a systematic review and network meta-analysis

“…Previous NMA (12) also showed that ropinirole did not improve the UPDRS II compared with placebo in early PD. Although other NMAs (8,(10)(11)(12) and meta-analyses (39) showed that ropinirole was associated with a significant improvement in the UPDRS-II compared with placebo, early PD and advanced PD were not analyzed separately, and ropinirole PR and ropinirole IR were not analyzed separately. Therefore, more research is needed to confirm the efficacy of ropinirole PR in early PD.…”

Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson’s Disease

“…Ropinirole primarily stimulates D2 and D3 receptors and has little affinity for D1, adrenergic and serotonergic receptors [ 125 ]. Ropinirole can be used as a monotherapy for early PD or in combination with levodopa for the management of advanced PD [ 126 ]. A randomized clinical study involving 161 early PD subjects found that ropinirole 24-hour sustained release and ropinirole immediate release showed similar efficiency in improving UPDRS motor score in early PD patients [ 127 ].…”

Parkinson's Disease — Overview of Modern Treatment Methods

“…Крім того, через можливе ураження клапанів серця агоністи дофаміну був практично виключений з медичної практики. Також нещодавне проведене дослідження іншого агоніста дофаміну ропініролу продемонструвало його ефективніть при ХП, зокрема на ранніх стадіях хвороби [22]. Обидва вище згадані препарати мають селективну активність щодо сайтів класу D2 (зокрема, щодо білківрецепторів D2 і D3) і незначну активність щодо сайтів класу D1.…”